Descovy

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

emtricitabine, tenofovir alafenamide

Available from:

Gilead Sciences Ireland UC

ATC code:

J05AR17

INN (International Name):

emtricitabine, tenofovir alafenamide

Therapeutic group:

Antivirusi za sistemsko uporabo

Therapeutic area:

Okužbe z virusom HIV

Therapeutic indications:

Descovy is indicated in combination with other antiretroviral agents for the treatment of adults and adolescents (aged 12 years and older with body weight at least 35 kg) infected with human immunodeficiency virus type 1 (HIV-1).

Product summary:

Revision: 20

Authorization status:

Pooblaščeni

Authorization date:

2016-04-21

Patient Information leaflet

                                61
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Gilead Sciences Ireland UC
Carrigtohill
County Cork, T45 DP77
Irska
12.
ŠTEVILKA(E) DOVOLJENJA(DOVOLJENJ) ZA PROMET
EU/1/16/1099/001 30 filmsko obloženih tablet
EU/1/16/1099/002
90 (3 plastenke po 30) filmsko obloženih tablet
EU/1/16/1099/005 60 (2 plastenki po 30) filmsko obloženih tablet
13.
ŠTEVILKA SERIJE
Lot
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
16.
PODATKI V BRAILLOVI PISAVI
Descovy 200 mg/10 mg [samo na zunanji ovojnini]
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC {številka}
SN {številka}
NN {številka}
62
PODATKI NA ZUNANJI OVOJNINI IN PRIMARNI OVOJNINI
OZNAČEVANJE NA PLASTENKI IN ŠKATLI
1.
IME ZDRAVILA
Descovy 200 mg/25 mg filmsko obložene tablete
emtricitabin/tenofoviralafenamid
2.
NAVEDBA ENE ALI VEČ UČINKOVIN
Ena filmsko obložena tableta vsebuje 200 mg emtricitabina in
tenofoviralafenamidijevega fumarata,
kar ustreza 25 mg tenofoviralafenamida.
3.
SEZNAM POMOŽNIH SNOVI
4.
FARMACEVTSKA OBLIKA IN VSEBINA
30 filmsko obloženih tablet
60 (2 plastenki po 30) filmsko obloženih tablet
90 (3 plastenke po 30) filmsko obloženih tablet
5.
POSTOPEK IN POT(I) UPORABE ZDRAVILA
Pred uporabo preberite priloženo navodilo!
peroralna uporaba
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v originalni ovojnini za zagotovitev zaščite pred vlago.
PLASTENKO SHRANJUJTE TESNO ZAPRTO.
63
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Gilead Sciences 
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Descovy 200 mg/10 mg filmsko obložene tablete
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Ena tableta vsebuje 200 mg emtricitabina in tenofoviralafenamidijev
fumarat v količini, ki ustreza
10 mg tenofoviralafenamida.
3.
FARMACEVTSKA OBLIKA
filmsko obložena tableta
Siva filmsko obložena tableta v obliki pravokotnika, z dimenzijami
12,5 mm x 6,4 mm, z vtisnjenim
znakom “GSI” na eni strani in “210” na drugi strani tablete.
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Zdravilo Descovy je indicirano v kombinaciji z drugimi
protiretrovirusnimi učinkovinami za
zdravljenje odraslih in mladostnikov (starih 12 let in več s telesno
maso vsaj 35 kg), okuženih z
virusom humane imunske pomanjkljivosti tipa 1 (HIV-1) (glejte poglavji
4.2 in 5.1).
4.2
ODMERJANJE IN NAČIN UPORABE
Terapijo mora začeti zdravnik, ki že ima izkušnje z zdravljenjem
okužbe z virusom HIV.
_ _
Odmerjanje
Zdravilo Descovy je treba dajati, kot je prikazano v preglednici 1.
_ _
PREGLEDNICA 1: ODMEREK ZDRAVILA DESCOVY GLEDE NA TRETJO UČINKOVINO V
REŽIMU ZDRAVLJENJA HIV
ODMEREK ZDRAVILA DESCOVY
TRETJE ZDRAVILO V REŽIMU ZDRAVLJENJA HIV
(glejte poglavje 4.5)
Descovy 200/10 mg enkrat
dnevno
Atazanavir z ritonavirjem ali kobicistatom
Darunavir z ritonavirjem ali kobicistatom
1
Lopinavir z ritonavirjem
Descovy 200/25 mg enkrat
dnevno
Dolutegravir, efavirenz, maravirok,
nevirapin, rilpivirin, raltegravir
1
Zdravilo Descovy 200/10 mg v kombinaciji z darunavirjem 800 mg in
kobicistatom 150 mg, dano kot tableta s fiksno
kombinacijo odmerkov, so preučili pri predhodno nezdravljenih osebah,
glejte poglavje 5.1.
_Izpuščeni odmerki_
Če bolnik izpusti odmerek zdravila Descovy v roku 18 ur od časa, ko
ga običajno vzame, naj vzame
zdravilo Descovy takoj, ko je mogoče, nato pa nadaljuje z običajnim
režimom odmerjanja. Če bolnik
izpusti odmerek zdravila Descovy za več kot 18 ur, naj ne nadomesti
izpuščenega odmerka in
preprosto nadaljuje z jemanjem po običajnem režimu odmerja
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-02-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-02-2023
Public Assessment Report Public Assessment Report Bulgarian 01-06-2016
Patient Information leaflet Patient Information leaflet Spanish 17-02-2023
Public Assessment Report Public Assessment Report Spanish 01-06-2016
Patient Information leaflet Patient Information leaflet Czech 17-02-2023
Public Assessment Report Public Assessment Report Czech 01-06-2016
Patient Information leaflet Patient Information leaflet Danish 17-02-2023
Public Assessment Report Public Assessment Report Danish 01-06-2016
Patient Information leaflet Patient Information leaflet German 17-02-2023
Public Assessment Report Public Assessment Report German 01-06-2016
Patient Information leaflet Patient Information leaflet Estonian 17-02-2023
Public Assessment Report Public Assessment Report Estonian 01-06-2016
Patient Information leaflet Patient Information leaflet Greek 17-02-2023
Public Assessment Report Public Assessment Report Greek 01-06-2016
Patient Information leaflet Patient Information leaflet English 17-02-2023
Public Assessment Report Public Assessment Report English 01-06-2016
Patient Information leaflet Patient Information leaflet French 17-02-2023
Public Assessment Report Public Assessment Report French 01-06-2016
Patient Information leaflet Patient Information leaflet Italian 17-02-2023
Public Assessment Report Public Assessment Report Italian 01-06-2016
Patient Information leaflet Patient Information leaflet Latvian 17-02-2023
Public Assessment Report Public Assessment Report Latvian 01-06-2016
Patient Information leaflet Patient Information leaflet Lithuanian 17-02-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-02-2023
Public Assessment Report Public Assessment Report Lithuanian 01-06-2016
Patient Information leaflet Patient Information leaflet Hungarian 17-02-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 17-02-2023
Public Assessment Report Public Assessment Report Hungarian 01-06-2016
Patient Information leaflet Patient Information leaflet Maltese 17-02-2023
Public Assessment Report Public Assessment Report Maltese 01-06-2016
Patient Information leaflet Patient Information leaflet Dutch 17-02-2023
Public Assessment Report Public Assessment Report Dutch 01-06-2016
Patient Information leaflet Patient Information leaflet Polish 17-02-2023
Public Assessment Report Public Assessment Report Polish 01-06-2016
Patient Information leaflet Patient Information leaflet Portuguese 17-02-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 17-02-2023
Public Assessment Report Public Assessment Report Portuguese 01-06-2016
Patient Information leaflet Patient Information leaflet Romanian 17-02-2023
Public Assessment Report Public Assessment Report Romanian 01-06-2016
Patient Information leaflet Patient Information leaflet Slovak 17-02-2023
Public Assessment Report Public Assessment Report Slovak 01-06-2016
Patient Information leaflet Patient Information leaflet Finnish 17-02-2023
Public Assessment Report Public Assessment Report Finnish 01-06-2016
Patient Information leaflet Patient Information leaflet Swedish 17-02-2023
Public Assessment Report Public Assessment Report Swedish 01-06-2016
Patient Information leaflet Patient Information leaflet Norwegian 17-02-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 17-02-2023
Patient Information leaflet Patient Information leaflet Icelandic 17-02-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 17-02-2023
Patient Information leaflet Patient Information leaflet Croatian 17-02-2023
Public Assessment Report Public Assessment Report Croatian 01-06-2016

Search alerts related to this product

View documents history